AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

Sponsor
Bursa City Hospital
Study ID
NCT07329543
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to experience fractures despite treatment. Advanced glycation end-products (AGEs) accumulate in the body over time and can negatively affect bone quality by altering collagen structure and increasing inflammation. The role of AGE burden in predicting response to osteoporosis treatment has not been fully established. This prospective cohort study aims to evaluate whether baseline AGE burden, measured non-invasively using skin autofluorescence, is associated with treatment response in patients receiving antiresorptive therapy for osteoporosis. Changes in bone mineral density, bone turnover markers, and fracture outcomes will be analyzed in relation to baseline AGE levels. The results of this study may help identify patients at risk for reduced treatment response and residual fracture risk.

Key Dates

Start date
Jan 15, 2026
Status verified
Jan 2026
Primary completion
Jan 15, 2027
Completion
Apr 15, 2027

Study Design

Enrollment
240 participants (estimated)

Arms

  • Arm: Denosumab Group
    Patients with osteoporosis receiving denosumab as part of routine clinical care.
  • Arm: Bisphosphonate Group
    Patients with osteoporosis receiving bisphosphonate therapy as part of routine clinical care.

Primary Outcome Measure

Percentage Change in Total Hip Bone Mineral Density [ Time Frame: Baseline to 12 months ]

Central Contacts

Related Studies